A large number of antibody assays are devoted to the study of nuclear excision repair (NER) proteins. However, there are a number of other DNA repair pathways, many of which are instigated by NER and share the same proteins. DNA repair antibodies are widely used in cancer research, and Novus Biologicals offers an extensive selection of thoroughly validated, high-quality DNA repair and cancer related antibodies.
NER is subdivided into global repair, which repairs damage to any part of the DNA structure, and transcription-coupled repair, which preferentially recognises damage in an area where simultaneous transcription is occurring. The mechanism by which this occurs is still not fully understood, though it is known that XPC is essential. Antibodystudies have shown that damage recognition and repair can be initiated by blocking RNA polymerase II, assisted by the Cockayne’s syndrome genes ERCC8 and ERCC6.
We at Novus Biologicals have 127 antibody products devoted to the area of mismatch repair. They are of importance in certain cancers specific cancers. For example, MLH1 is frequently mutated in cases of hereditary nonpolyposis colon cancer. It is a homologue of the E. coli mismatch repair gene mutS.
Immunoperoxidase of monoclonal antibody to MLH1
Mismatch repair proteins recognize and repair incorrect insertions and deletions of base pairs, such as guanine–thymine or adenine-cytosine. These mismatches can occur through replication errors, oxidation, methylation, spontaneous deamination and as intermediates of homologous recombination (HR). Mismatch repair involves excision of the faulty base pair, replacing it with the correct sequence. It is often instigated through NER, though HR and BER (base excision repair) are also involved. BER antibodies are often used in brain cancer studies – BER is the main mismatch pathway in the brain.
Novus Biologicals offers many MLH1 reagents for your research needs including:
